BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
154.8 EUR
+7.75 (+5.27%)
Taking everything into account, IDP scores 6 out of 10 in our fundamental rating. IDP was compared to 83 industry peers in the Biotechnology industry. IDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDP has a bad growth rate and is valued cheaply. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IDP (5.51%) is better than 79.52% of its industry peers.
Looking at the Return On Equity, with a value of 8.84%, IDP belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
IDP's Return On Invested Capital of 9.70% is amongst the best of the industry. IDP outperforms 87.95% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is in line with the industry average of 11.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
The Profit Margin of IDP (15.98%) is better than 81.93% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
The Operating Margin of IDP (28.50%) is better than 87.95% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 75.24%, IDP is doing good in the industry, outperforming 65.06% of the companies in the same industry.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
Compared to 1 year ago, IDP has more shares outstanding
IDP has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
IDP has an Altman-Z score of 3.27. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
IDP's Altman-Z score of 3.27 is fine compared to the rest of the industry. IDP outperforms 72.29% of its industry peers.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
IDP has a better Debt to FCF ratio (2.78) than 80.72% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
IDP's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. IDP outperforms 54.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.27 |
ROIC/WACC1.18
WACC8.25%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 56.63% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
IDP's Quick ratio of 2.04 is in line compared to the rest of the industry. IDP outperforms 49.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.56% yearly.
Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.63% on average per year.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.86, which indicates a very decent valuation of IDP.
92.77% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of IDP to the average of the S&P500 Index (27.17), we can say IDP is valued rather cheaply.
With a Price/Forward Earnings ratio of 11.77, the valuation of IDP can be described as very reasonable.
96.39% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
IDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.86 | ||
| Fwd PE | 11.77 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 89.16% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 93.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.79 | ||
| EV/EBITDA | 7.59 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/6/2026, 7:00:00 PM)
154.8
+7.75 (+5.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap22.71B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.43 (0.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)0.32%
PT rev (3m)4.91%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.86%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.86 | ||
| Fwd PE | 11.77 | ||
| P/S | 2.65 | ||
| P/FCF | 11.79 | ||
| P/OCF | 10.87 | ||
| P/B | 1.47 | ||
| P/tB | 11.19 | ||
| EV/EBITDA | 7.59 |
EPS(TTM)14.25
EY9.21%
EPS(NY)13.16
Fwd EY8.5%
FCF(TTM)13.13
FCFY8.48%
OCF(TTM)14.23
OCFY9.2%
SpS58.4
BVpS105.63
TBVpS13.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.27 |
F-Score5
WACC8.25%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.